<DOC>
	<DOC>NCT02377440</DOC>
	<brief_summary>The investigators hypothesize that older persons (â‰¥45 years) treated with ACEI for HTN control will have: i) improved status of bone turnover (decreased P1NP and CTX), and ii) decreased levels of RANKL and RANKL/OPG, compared to those not treated with ACEI and not using RAS-related medications</brief_summary>
	<brief_title>Effects of ACEI on Bone Turnover</brief_title>
	<detailed_description />
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>at least 45 years of age a diagnosis of (either new or uncontrolled) HTN who will need a new medication for HTN control able to consent (no medial issues impairing judgment for consenting based on clinical providers' judgment). younger than 45 years of age a diagnosis of metabolic bone disease a diagnosis of osteoporosis or use of medication to treat osteoporosis a diagnosis of diabetes mellitus, or renal insufficiency, or cancer history of allergy to ACEI or ARB, 6) history of use of ACEI or ARB.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ACE inhibitor</keyword>
</DOC>